A Phase I, open label study of extended dosing with PatrinTM in combination with temozolomide in the treatment of patients with advanced melanoma.
Phase 1
Recruiting
- Conditions
- Advanced melanomaCancer - Malignant melanoma
- Registration Number
- ACTRN12605000625673
- Lead Sponsor
- KuDOS Pharmaceuticals Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 132
Inclusion Criteria
Unresectable stage 3 /4 measurable (RECIST criteria), histologically proven cutaneous melanoma or unknown primary with melanoma metastases, without systemic treatment for metastatic disease.
Exclusion Criteria
No exclusion criteria
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method